Form 4: Mineralys Therapeutics' Chief Medical Officer Sells Shares Under 10b5-1 Trading Plan
SEC Form 4 Filing
David Malcom Rodman, Chief Medical Officer of Mineralys Therapeutics, sold 11,366 shares of common stock at a weighted-average price of $15.2889 on May 14, 2025, under a pre-arranged 10b5-1 trading plan.
Summary
- On May 14, 2025, David Malcom Rodman, the Chief Medical Officer of Mineralys Therapeutics, sold 11,366 shares of common stock.
- The sale was executed at a weighted-average price of $15.2889 per share.
- The transactions occurred within a price range of $14.9100 to $15.7726.
- This sale was conducted under a Rule 10b5-1 trading plan adopted on October 25, 2024.
- Following the transaction, Rodman directly owns 106,669 shares of Mineralys Therapeutics.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing an insider stock sale under a pre-arranged trading plan. It doesn't inherently convey positive or negative sentiment.
Industry Context
This Form 4 filing is a routine disclosure of insider trading activity. It is common for executives to utilize 10b5-1 trading plans to sell shares over time to avoid accusations of trading on inside information.
Stakeholder Impact
- The sale of shares by a company executive could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.
Key Dates
| Date | Description |
|---|---|
| 2024-10-25 | Date of adoption of Rule 10b5-1 trading plan. |
| 2025-05-14 | Date of stock sale transaction. |
| 2025-05-15 | Date of Form 4 filing. |
Keywords
Mineralys Therapeutics, David Malcom Rodman, Chief Medical Officer, stock sale, Form 4, Rule 10b5-1, insider trading, MLYS
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.